Bill H. Chang

7.3k total citations · 1 hit paper
76 papers, 3.2k citations indexed

About

Bill H. Chang is a scholar working on Molecular Biology, Hematology and Public Health, Environmental and Occupational Health. According to data from OpenAlex, Bill H. Chang has authored 76 papers receiving a total of 3.2k indexed citations (citations by other indexed papers that have themselves been cited), including 36 papers in Molecular Biology, 29 papers in Hematology and 28 papers in Public Health, Environmental and Occupational Health. Recurrent topics in Bill H. Chang's work include Acute Lymphoblastic Leukemia research (28 papers), Chronic Lymphocytic Leukemia Research (22 papers) and Chronic Myeloid Leukemia Treatments (20 papers). Bill H. Chang is often cited by papers focused on Acute Lymphoblastic Leukemia research (28 papers), Chronic Lymphocytic Leukemia Research (22 papers) and Chronic Myeloid Leukemia Treatments (20 papers). Bill H. Chang collaborates with scholars based in United States, Canada and India. Bill H. Chang's co-authors include Thomas R. Soderling, Brian Druker, Jeffrey Tyner, Sucheta Mukherji, Debra A. Brickey, Marc Loriaux, Peter Kurre, Shannon K. McWeeney, Noah I. Hornick and Natalya A. Goloviznina and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and Journal of Biological Chemistry.

In The Last Decade

Bill H. Chang

69 papers receiving 3.2k citations

Hit Papers

OncogenicCSF3RMutations i... 2013 2026 2017 2021 2013 100 200 300
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. OncogenicCSF3RMutations in Chronic Neutrophilic Leukemia and Atypical CML
    2013 356 citations Julia E. Maxson, Jason Gotlib et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Bill H. Chang United States 28 1.9k 823 645 440 424 76 3.2k
Stephen Meek United Kingdom 18 2.4k 1.3× 540 0.7× 407 0.6× 672 1.5× 334 0.8× 29 3.8k
Lawryn H. Kasper United States 22 2.7k 1.4× 458 0.6× 501 0.8× 276 0.6× 387 0.9× 26 3.6k
Malek Faham United States 27 1.5k 0.8× 682 0.8× 1.2k 1.8× 435 1.0× 748 1.8× 92 4.2k
Gary Brown United States 12 2.1k 1.1× 362 0.4× 410 0.6× 259 0.6× 226 0.5× 14 3.0k
Lisa Garrett United States 25 3.1k 1.7× 346 0.4× 1.3k 2.0× 235 0.5× 503 1.2× 50 5.0k
Kunio Kitamura Japan 32 2.1k 1.1× 500 0.6× 487 0.8× 192 0.4× 123 0.3× 92 3.4k
Teresa V. Bowman United States 23 2.5k 1.3× 758 0.9× 331 0.5× 274 0.6× 353 0.8× 55 4.0k
Philippe Jonveaux France 31 2.1k 1.1× 1.2k 1.4× 511 0.8× 538 1.2× 236 0.6× 134 4.1k
Megumu Ogawa Japan 32 2.6k 1.4× 863 1.0× 635 1.0× 467 1.1× 176 0.4× 71 4.6k
Ralf Dressel Germany 32 2.5k 1.3× 289 0.4× 387 0.6× 300 0.7× 186 0.4× 107 4.1k

Countries citing papers authored by Bill H. Chang

Since Specialization
Citations

This map shows the geographic impact of Bill H. Chang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bill H. Chang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bill H. Chang more than expected).

Fields of papers citing papers by Bill H. Chang

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Bill H. Chang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bill H. Chang. The network helps show where Bill H. Chang may publish in the future.

Co-authorship network of co-authors of Bill H. Chang

This figure shows the co-authorship network connecting the top 25 collaborators of Bill H. Chang. A scholar is included among the top collaborators of Bill H. Chang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Bill H. Chang. Bill H. Chang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Eide, Christopher A., Stephen E. Kurtz, Andy Kaempf, et al.. (2023). Clinical Correlates of Venetoclax-Based Combination Sensitivities to Augment Acute Myeloid Leukemia Therapy. Blood Cancer Discovery. 4(6). 452–467. 12 indexed citations
3.
Kurtz, Stephen E., Christopher A. Eide, Andy Kaempf, et al.. (2022). Associating drug sensitivity with differentiation status identifies effective combinations for acute myeloid leukemia. Blood Advances. 6(10). 3062–3067. 6 indexed citations
4.
5.
Leonard, Jessica, Yoko Kosaka, Dorian LaTocha, et al.. (2020). Concomitant use of a dual Src/ABL kinase inhibitor eliminates the in vitro efficacy of blinatumomab against Ph+ ALL. Blood. 137(7). 939–944. 17 indexed citations
6.
Eide, Christopher A., Stephen E. Kurtz, Andy Kaempf, et al.. (2020). Simultaneous kinase inhibition with ibrutinib and BCL2 inhibition with venetoclax offers a therapeutic strategy for acute myeloid leukemia. Leukemia. 34(9). 2342–2353. 16 indexed citations
7.
Nechiporuk, Tamilla, Stephen E. Kurtz, Olga Nikolova, et al.. (2019). The TP53 Apoptotic Network Is a Primary Mediator of Resistance to BCL2 Inhibition in AML Cells. Cancer Discovery. 9(7). 910–925. 222 indexed citations
8.
Rivera‐Mulia, Juan Carlos, Takayo Sasaki, Claudia Trevilla‐García, et al.. (2019). Replication timing alterations in leukemia affect clinically relevant chromosome domains. Blood Advances. 3(21). 3201–3213. 16 indexed citations
9.
Eide, Christopher A., Stephen E. Kurtz, Andy Kaempf, et al.. (2019). Simultaneous Kinase Inhibition with Ibrutinib and BCL2 Inhibition with Venetoclax As a Therapeutic Strategy for Acute Lymphoblastic Leukemia. Blood. 134(Supplement_1). 3950–3950.
10.
Chow, M, Lina Gao, Jason D. MacManiman, et al.. (2018). Maintenance and pharmacologic targeting of ROR1 protein levels via UHRF1 in t(1;19) pre-B-ALL. Oncogene. 37(38). 5221–5232. 11 indexed citations
11.
Leonard, Jessica, Yoko Kosaka, Adam J. Lamble, et al.. (2018). Altered T Cell Subsets and Function in Patients with Acute Lymphoblastic Leukemia. Blood. 132(Supplement 1). 1547–1547.
12.
Chang, Bill H., Jessica Leonard, Beth Wilmot, et al.. (2018). Significant In Vivo Sensitivity to Aurora Kinase Inhibition in TCF3-Hlf rearranged Acute Lymphoblastic Leukemia. Blood. 132(Supplement 1). 4026–4026.
13.
Sasaki, Takayo, Juan Carlos Rivera‐Mulia, Daniel L. Vera, et al.. (2017). Stability of patient-specific features of altered DNA replication timing in xenografts of primary human acute lymphoblastic leukemia. Experimental Hematology. 51. 71–82.e3. 21 indexed citations
14.
Cooper, Todd M., Elena Eckroth, Jemily Malvar, et al.. (2016). A Phase I Study of Quizartinib Combined with Chemotherapy in Relapsed Childhood Leukemia: A Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) Study. Clinical Cancer Research. 22(16). 4014–4022. 56 indexed citations
15.
Maxson, Julia E., Monika A. Davare, Samuel B. Luty, et al.. (2015). Therapeutically Targetable ALK Mutations in Leukemia. Cancer Research. 75(11). 2146–2150. 17 indexed citations
16.
Chang, Bill H., Kara Johnson, Dorian LaTocha, et al.. (2015). YM155 potently kills acute lymphoblastic leukemia cells through activation of the DNA damage pathway. Journal of Hematology & Oncology. 8(1). 39–39. 31 indexed citations
17.
Tyner, Jeffrey, Armand Bankhead, Guang Fan, et al.. (2012). Kinase Pathway Dependence in Primary Human Leukemias Determined by Rapid Inhibitor Screening. Cancer Research. 73(1). 285–296. 100 indexed citations
18.
Chang, Bill H., Stephanie G. Willis, Linda C. Stork, et al.. (2009). Mutational Analysis of BCR-Abl From Subjects with Relapsed Ph+ALL Treated On the COG Protocol AALL0031: a Report From the Children's Oncology Group.. Blood. 114(22). 2634–2634. 1 indexed citations
19.
Chang, Bill H., Alison Edelman, & Kamar Godder. (2007). Management of menstrual bleeding and cycle control after hematopoietic stem cell transplant. International Journal of Gynecology & Obstetrics. 100(1). 76–77. 2 indexed citations
20.
Huang, Wei, Yun Fu, Bill H. Chang, et al.. (1998). Sequence variation in ZFX introns in human populations. Molecular Biology and Evolution. 15(2). 138–142. 12 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Stephen Meek Breakdown of academic impact, for papers by Lawryn H. Kasper Breakdown of academic impact, for papers by Malek Faham Breakdown of academic impact, for papers by Gary Brown Breakdown of academic impact, for papers by Lisa Garrett Breakdown of academic impact, for papers by Kunio Kitamura Breakdown of academic impact, for papers by Teresa V. Bowman Breakdown of academic impact, for papers by Philippe Jonveaux Breakdown of academic impact, for papers by Megumu Ogawa Breakdown of academic impact, for papers by Ralf Dressel
Rankless by CCL
2026